Lower courts “relied at every stage on patently unreliable witnesses and studies,” the ACLU said in its amicus brief.
By Chris Walker, TRUTHOUT
An amicus brief — or “friend of the court” petition — submitted to the U.S. Supreme Court by the American Civil Liberties Union (ACLU) urges justices of the High Court to reject lower court orders that have sought to severely curtail access to abortion medication known as mifepristone.

The drug is used in a majority of abortions across the country, and is currently approved for up to 10 weeks of pregnancy. Deregulation of its use during the COVID-19 pandemic (and following the Court’s overturn of Roe v. Wade in June 2022) allowed for the drug to be more widely available, permitting doctors to prescribe it through telemedicine and letting it be sent to patients through the mail.
However, actions by a far right federal judge in Texas, as well as affirmation of parts of that judgment from a conservative appellate court, now threaten access to the drug for those who want or need it. Both opinions, the ACLU writes in its brief to the Supreme Court, were based on “junk science.”
Recent Posts
Militarized Immigration Enforcement Incompatible With Democracy
February 1, 2026
Take Action NowICE’s targeting of virtually anyone who is not white and English-speaking — including, ironically, Native Americans — exposes this…
Trump’s Back-and-Forth Threats on Iran Are Psychological Warfare
January 31, 2026
Take Action NowAs Trump threatens Iran yet again, Congress continues to abdicate its responsibility to rein in war.By Hanieh Jodat, Truthout As…
U.S. Media Keen on Iranian Unrest—Less So on U.S. and Israel’s Role in It
January 30, 2026
Take Action Now Democrats have a rare moment of leverage to pass legislation ending qualified immunity for Immigration and Customs Enforcement…
The Senate Must Not Fund ICE, A Zero Hour Conversation With Sonali Kolhatkar
January 30, 2026
Take Action Now “We’ve seen a really sharp change in how the public views immigration enforcement, particularly ice, to the point where…



